Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts.
[severe combined immunodeficiency]
The
Notch
ligand
Delta
-like
4
(
Dll
4
)
is
highly
expressed
in
vascular
endothelium
and
has
been
shown
to
play
a
pivotal
role
in
regulating
tumor
angiogenesis
.
Blockade
of
the
Dll
4
-
Notch
pathway
in
preclinical
cancer
models
has
been
associated
with
non-productive
angiogenesis
and
reduced
tumor
growth
.
Given
the
cross-talk
between
the
vascular
endothelial
growth
factor
(
VEGF
)
and
Delta
-
Notch
pathways
in
tumor
angiogenesis
,
we
examined
the
activity
of
a
function-blocking
Dll
4
antibody
,
REGN
1035
,
alone
and
in
combination
with
anti-
VEGF
therapy
in
renal
cell
carcinoma
(
RCC
)
.
Severe
combined
immunodeficiency
(
SCID
)
mice
bearing
patient-derived
clear
cell
RCC
xenografts
were
treated
with
REGN
1035
and
in
combination
with
the
multi-targeted
tyrosine
kinase
inhibitor
sunitinib
or
the
VEGF
blocker
ziv
-aflibercept
.
Immunohistochemical
and
immunofluorescent
analyses
were
carried
out
,
as
well
as
magnetic
resonance
imaging
(
MRI
)
examinations
pre
and
24
hours
and
2
weeks
post
treatment
.
Single
agent
treatment
with
REGN
1035
resulted
in
significant
tumor
growth
inhibition
(
36
-
62
%
)
that
was
equivalent
to
or
exceeded
the
single
agent
anti-
tumor
activity
of
the
VEGF
pathway
inhibitors
sunitinib
(
38
-
54
%
)
and
ziv
-aflibercept
(
46
%
)
.
Importantly
,
combination
treatments
with
REGN
1035
plus
VEGF
inhibitors
resulted
in
enhanced
anti-
tumor
effects
(
72
-
80
%
growth
inhibition
)
,
including
some
tumor
regression
.
Magnetic
resonance
imaging
showed
a
marked
decrease
in
tumor
perfusion
in
all
treatment
groups
.
Interestingly
,
anti-
tumor
efficacy
of
the
combination
of
REGN
1035
and
ziv
-aflibercept
was
also
observed
in
a
sunitinib
resistant
ccRCC
model
.
Overall
,
these
findings
demonstrate
the
potent
anti-
tumor
activity
of
Dll
4
blockade
in
RCC
patient-derived
tumors
and
a
combination
benefit
for
the
simultaneous
targeting
of
the
Dll
4
and
VEGF
signaling
pathways
,
highlighting
the
therapeutic
potential
of
this
treatment
modality
in
RCC
.
Diseases
Validation
Diseases presenting
"growth factor"
symptom
22q11.2 deletion syndrome
achondroplasia
adrenal incidentaloma
aniridia
cadasil
cholangiocarcinoma
coats disease
dedifferentiated liposarcoma
dentin dysplasia
dentinogenesis imperfecta
dystrophic epidermolysis bullosa
esophageal carcinoma
esophageal squamous cell carcinoma
hodgkin lymphoma, classical
holt-oram syndrome
inclusion body myositis
kallmann syndrome
krabbe disease
liposarcoma
lymphangioleiomyomatosis
oculocutaneous albinism
oral submucous fibrosis
pleomorphic liposarcoma
primary effusion lymphoma
primary hyperoxaluria type 1
severe combined immunodeficiency
systemic capillary leak syndrome
von hippel-lindau disease
wolf-hirschhorn syndrome
x-linked adrenoleukodystrophy
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom